495P Safety and efficacy of nab-sirolimus (HB1901) + endocrine therapy in HR+/HER2- advanced breast cancer after standard therapy failure: A multicenter, open-label, phase 2 study
Fei Ma(Chinese Academy of Medical Sciences & Peking Union Medical College), Fang Luo(Ningxia University), Yipengchen Yin(Jiangsu Province Hospital), Hongfu Sun(Jiamusi University), Lu Gan(Thomas Jefferson University), Ye Lv(Dalian Medical University), Cheng Xia(Affiliated Hospital of Jining Medical University), Tao Sun(Wuhan University), Jie Cui(Albert Einstein College of Medicine), Zhenchuan Song(Hebei Medical University), Hongnan Mo(Chinese Academy of Medical Sciences & Peking Union Medical College), Ying Liu(Zhengzhou University), Li Wang, Chi Wang(Markey Cancer Center), Xiaofeng Wang(Virginia Tech), Bing Zhao(Xinjiang Medical University), Xuxinyi Ling(First Hospital of Lanzhou University), Fei Xu(Sun Yat-sen University)
Cited by 0
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Correction: Corrigendum: The Serum Profile of Hypercytokinemia Factors Identified in H7N9-Infected Patients can Predict Fatal Outcomes
|Scientific Reports|2016|2.1k
Deep convolutional neural networks for multi-modality isointense infant brain image segmentation
|NeuroImage|2015|830
Deep Learning Based Imaging Data Completion for Improved Brain Disease Diagnosis
|Lecture notes in computer science|2014|485
Mapping transcriptomic vector fields of single cells
|Cell|2022|475